Therapeutic ERCP (Endoscopic Retrograde Cholangiopancreatography) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Therapeutic ERCP (Endoscopic Retrograde Cholangiopancreatography) is a minimally invasive endoscopic procedure that combines flexible endoscopy with real-time X-ray fluoroscopy to perform direct interventions on the bile ducts and pancreatic ducts — without open abdominal surgery. Unlike diagnostic ERCP, which only images these ductal structures, therapeutic ERCP actively treats pathology: removing stones, dilating strictures, placing stents, sealing bile leaks, and sampling tissue.

The procedure is performed by a trained interventional gastroenterologist using a side-viewing duodenoscope — a long flexible camera — passed through the mouth, oesophagus, stomach, and into the duodenum. The scope's elevator mechanism guides a cannula into the ampulla of Vater, the shared opening of the bile and pancreatic ducts. Contrast dye is injected and fluoroscopic images are obtained; then therapeutic accessories such as sphincterotomes, extraction baskets, balloons, and stents are deployed through the working channel of the scope.

First introduced in the early 1970s, therapeutic ERCP has revolutionised the management of biliary and pancreatic disease, replacing open common bile duct exploration in the vast majority of patients. Major international guidelines from the American Society for Gastrointestinal Endoscopy (ASGE), the European Society of Gastrointestinal Endoscopy (ESGE), and the British Society of Gastroenterology (BSG) endorse therapeutic ERCP as the first-line interventional approach for choledocholithiasis and acute cholangitis.

The procedure typically takes 30 to 90 minutes depending on complexity. Most patients are observed for 2 to 4 hours in recovery and discharged the same day, though complex interventions or complications may require an overnight stay. Therapeutic ERCP carries a well-defined risk profile — most notably post-ERCP pancreatitis — and patient selection, procedural technique, and pharmacological prophylaxis are all critical to optimising safety and outcomes.

Therapeutic ERCP is the primary interventional treatment for a wide range of biliary and pancreatic conditions. The most common indications include:

• Choledocholithiasis (Common Bile Duct Stones): The most frequent indication globally. Stones are removed by sphincterotomy followed by balloon sweep or basket extraction. Success rates exceed 90% for standard stones in a single session.
• Acute Cholangitis: Bacterial infection of the bile duct secondary to obstruction. Emergency biliary decompression via ERCP is life-saving and recommended within 24 to 72 hours of diagnosis according to the Tokyo Guidelines.
• Biliary Strictures: Narrowings caused by primary sclerosing cholangitis (PSC), post-cholecystectomy scarring, or compression from pancreatic cancer are dilated and stented to restore bile flow and prevent cholestasis-related liver damage.
• Bile Leaks: Post-surgical or traumatic bile leaks from the cystic duct stump or main bile duct are sealed by placing a transpapillary biliary stent that equalises ductal pressure and diverts bile centrally.
• Malignant Biliary Obstruction: Cholangiocarcinoma and pancreatic head cancers causing jaundice are palliated by placement of self-expanding metal stents (SEMS), restoring biliary drainage and improving quality of life.
• Pancreatic Duct Strictures and Stones: Pancreatic sphincterotomy, ductal dilation, and stent placement relieve chronic pancreatitis pain caused by outflow obstruction and elevated intraductal pressure.
• Ampullary Adenomas: Endoscopic papillectomy via ERCP can excise benign ampullary tumours, avoiding major pancreaticoduodenectomy in select patients.
• Mirizzi Syndrome: Extrinsic compression of the common hepatic duct by an impacted gallbladder stone is managed by biliary stenting as a bridge to definitive surgery.

Therapeutic ERCP is appropriate for patients with documented biliary or pancreatic pathology confirmed on prior imaging. Careful patient selection minimises procedural risk. Key eligibility criteria include:

• Confirmed Therapeutic Indication: ERCP should only be performed when an intervention is planned. Purely diagnostic questions should first be addressed by MRCP or endoscopic ultrasound (EUS), which provide equivalent accuracy without procedural risk.
• Adequate Cardiopulmonary Reserve: Patients must tolerate conscious sedation or monitored anaesthesia care. Those with severe cardiac or respiratory compromise may require anaesthetist-led deep sedation or general anaesthesia in selected cases.
• Coagulation Status: Guidelines recommend correcting coagulopathy (INR below 1.5) and ensuring platelet count above 50,000 per microlitre before sphincterotomy. Anticoagulants such as warfarin and direct oral anticoagulants are typically held 5 to 7 days pre-procedure; antiplatelet agents are managed according to individual bleeding and thrombotic risk.
• Normal Upper Gastrointestinal Anatomy: Prior Billroth II gastrectomy, Roux-en-Y reconstruction, or hepaticojejunostomy alters anatomy significantly. These cases require specialised enteroscopy-assisted ERCP or a hybrid percutaneous approach and should be referred to expert centres.
• Absence of Active Pancreatitis: ERCP is deferred in acute pancreatitis unless coexisting cholangitis or persistent biliary obstruction is present. Performing ERCP during active uncomplicated acute pancreatitis does not improve outcomes and may worsen pancreatic inflammation.

Relative contraindications include severe iodinated contrast allergy (requiring pre-medication with corticosteroids and antihistamines, or CO2 cholangiography) and significant duodenal obstruction limiting papillary access. Advanced age alone is not a contraindication; therapeutic ERCP is safely performed in octogenarians with appropriate risk modification and informed consent.

Therapeutic ERCP encompasses a spectrum of interventional techniques selected based on the underlying pathology and anatomical complexity:

• Endoscopic Sphincterotomy (EST): A sphincterotome wire is used to cut the sphincter of Oddi, widening the bile duct opening to allow stone passage or instrument access. This is the foundational step for most biliary therapeutic interventions and takes only minutes once cannulation is achieved.
• Balloon Sweeping and Basket Extraction: Extraction balloons are inflated above bile duct stones and withdrawn to sweep them into the duodenum. Dormia baskets capture and retrieve individual stones. These techniques are used in combination for multiple or large stones.
• Endoscopic Papillary Balloon Dilation (EPBD): An alternative to sphincterotomy that preserves sphincter function by dilating the papilla with a controlled-radial-expansion balloon. Preferred in patients with coagulopathy or high bleeding risk, and in younger patients to reduce long-term risk of bacterial cholangitis.
• Mechanical Lithotripsy: Large stones (greater than 15 mm) that cannot be removed intact are crushed within a mechanical lithotripter basket before extraction. SpyGlass-guided intraductal laser lithotripsy (holmium laser) or electrohydraulic lithotripsy (EHL) is used for impacted or very large stones with reported clearance rates above 90%.
• Plastic Biliary Stenting: Plastic stents (7 to 10 French) provide temporary biliary drainage and are replaced every 3 to 6 months to prevent occlusion. Used for benign strictures, bile leaks, and as temporary palliation pending surgery or metal stent placement.
• Self-Expanding Metal Stents (SEMS): Uncovered or covered metal stents are placed for malignant biliary obstruction with patency rates of 8 to 12 months. Fully covered SEMS are preferred for benign biliary strictures as they are removable.
• Pancreatic Duct Interventions: Pancreatic sphincterotomy, pancreatic duct stenting, and pancreatic stone extraction (with or without extracorporeal shock wave lithotripsy) are performed for chronic pancreatitis with painful ductal obstruction.
• SpyGlass Direct Cholangioscopy: A single-operator per-oral cholangioscopy system enabling direct bile duct visualisation, targeted biopsy under direct vision, and lithotripsy of difficult stones that resist conventional techniques.

Therapeutic ERCP offers substantial advantages over surgical alternatives for the management of biliary and pancreatic disease:

• Minimally Invasive with No Incision: The entire procedure is performed through the natural orifice (mouth), eliminating surgical wounds, abdominal scarring, and wound-related complications such as infection and hernia.
• High Clinical Success Rates: Stone clearance is achieved in 90 to 95% of cases for standard common bile duct stones. Biliary decompression for obstruction succeeds in over 95% of patients with accessible papillary anatomy. Complex stones cleared with advanced lithotripsy techniques push overall success above 97%.
• Rapid Recovery: Most patients resume a normal diet within 24 hours and return to sedentary work within 2 to 3 days, compared to 4 to 6 weeks recovery for open common bile duct exploration surgery.
• Avoids General Anaesthesia in Most Cases: Conscious sedation is sufficient for the majority of therapeutic ERCPs, significantly reducing anaesthetic-related risk in elderly, frail, or comorbid patients.
• Simultaneous Diagnosis and Treatment: Cholangiography, tissue sampling, stone extraction, and stent placement can all be accomplished in a single session, avoiding multiple procedural admissions.
• Life-Saving in Acute Cholangitis: Emergency biliary decompression via therapeutic ERCP within 24 to 72 hours of acute cholangitis onset reduces mortality from septic shock, systemic inflammatory response, and multiorgan failure compared to delayed surgical drainage.
• Durable Results: Sphincterotomy provides permanent widening of the bile duct outlet. Complete stone clearance is definitive in most patients. Stents provide months to years of symptom control in benign and malignant disease.
• Cost-Effectiveness: Outpatient or short-stay therapeutic ERCP is substantially less costly than equivalent open surgical procedures, and avoids ICU admission in the management of acute cholangitis.

Therapeutic ERCP is a technically demanding procedure with a well-characterised complication profile. Informed consent must address the following risks:

• Post-ERCP Pancreatitis (PEP): The most common serious complication, occurring in 3 to 5% of average-risk patients and up to 10 to 15% in high-risk patients (young women, suspected sphincter of Oddi dysfunction, difficult cannulation, multiple pancreatic duct contrast injections). Most cases are mild to moderate and managed with intravenous fluids and analgesia over 3 to 5 days. Severe PEP requiring ICU admission occurs in 0.3 to 0.5% of all ERCPs. Evidence-based prevention: rectal indomethacin 100 mg administered immediately post-procedure reduces PEP incidence by approximately 50%; prophylactic pancreatic duct stenting further reduces risk in the highest-risk patients.
• Post-Sphincterotomy Bleeding: Occurs in 1 to 2% of cases, more frequently in patients on anticoagulants, those with portal hypertension, or with low platelet count. Immediate endoscopic haemostasis (diluted adrenaline injection, thermal coagulation, haemostatic clips) achieves control in the majority; angiographic embolisation or surgery is rarely needed.
• Post-ERCP Cholangitis: Bacterial infection of the bile duct occurs in approximately 1% of cases, usually when biliary drainage achieved during ERCP is incomplete. Prophylactic broad-spectrum antibiotics are recommended when complete drainage is uncertain.
• Perforation: Duodenal or retroperitoneal perforation — most commonly from sphincterotomy — occurs in under 1% of cases. Small perforations may be managed conservatively (bowel rest, antibiotics, nasogastric drainage) or closed endoscopically with clips; large perforations or peritonitis require emergency surgery.
• Contrast Reactions: Rare with modern non-ionic iodinated contrast media. Pre-medication with corticosteroids and antihistamines is recommended in patients with documented prior contrast allergy.
• Stent Occlusion and Migration: Plastic biliary stents have a median patency of 3 to 6 months before occlusion; blocked stents cause cholangitis. Routine endoscopic stent exchange is therefore planned at 3-monthly intervals for ongoing use.

Overall 30-day procedure-attributable mortality is below 0.5% for elective therapeutic ERCP, rising in emergency cholangitis where underlying disease severity is the primary contributor to mortality risk.

After therapeutic ERCP, patients are monitored in a recovery area for 2 to 4 hours before discharge. Structured follow-up is essential for detecting complications and confirming therapeutic success.

• Immediate Post-Procedure Monitoring: Vital signs, abdominal pain, and alertness are assessed before discharge. Serum amylase or lipase is checked at 2 to 4 hours in high-risk patients. Rising amylase combined with pain signals post-ERCP pancreatitis and prompts overnight admission for intravenous fluids and close monitoring.
• Diet Resumption: Clear fluids are permitted 2 hours post-procedure if the patient is comfortable and alert. A light diet is usually tolerated by the evening of the procedure. Normal diet resumes within 24 hours in uncomplicated cases.
• Activity and Driving: Patients must not drive for 24 hours due to residual sedation effects. Heavy physical lifting is restricted for 48 to 72 hours, particularly following sphincterotomy where bleeding risk is higher in the first few days.
• Medications: NSAIDs and anticoagulants are typically withheld for 5 to 7 days after sphincterotomy to reduce bleeding risk. Anticoagulation is restarted under clinician supervision once the sphincterotomy site is considered healed.
• Stent Surveillance: Patients with plastic biliary stents require planned repeat ERCP for stent exchange every 3 to 6 months. Patients with metal stents in malignant disease are followed clinically and with imaging; endoscopic restenting is arranged if stent occlusion is suspected.
• Imaging Follow-Up: MRCP or abdominal ultrasound at 4 to 6 weeks confirms stone clearance and assesses biliary anatomy. Patients with PSC, benign biliary strictures, or pancreatic duct disease require long-term surveillance imaging every 6 to 12 months.
• Alarm Symptoms Requiring Urgent Review: Fever above 38.5 degrees Celsius, worsening abdominal pain, jaundice, dark urine, or pale stools after ERCP should prompt immediate hospital attendance to exclude cholangitis, pancreatitis, or bile duct injury.

The cost of therapeutic ERCP varies widely by country, hospital tier, procedural complexity, and the type of intervention performed.

• Country and Healthcare System: ERCP costs range from approximately USD 1,500 to 3,000 in India, Thailand, and Malaysia to USD 8,000 to 20,000 in the United States and Australia. Medical tourism to JCI-accredited hospitals in India, Turkey, Singapore, and Eastern Europe offers savings of 60 to 80% on comparable quality.
• Hospital Tier and Accreditation: Tertiary academic hospitals with dedicated advanced endoscopy units and 24-hour biliary emergency services command premium pricing but offer lower failure rates, access to SpyGlass cholangioscopy, and expert management of complications.
• Procedural Complexity: Simple CBD stone extraction with sphincterotomy and balloon sweep is less expensive than multi-session stenting, SpyGlass cholangioscopy, mechanical or laser lithotripsy, or combined biliary and pancreatic interventions, which require additional time, consumables, and specialist expertise.
• Stent Type: Plastic stents cost USD 50 to 150 per unit but require periodic replacement adding cumulative cost. Self-expanding metal stents cost USD 800 to 2,500 each but offer longer patency, reducing re-intervention frequency in malignant obstruction.
• Anaesthesia Type: Procedures performed under anaesthetist-administered deep sedation or general anaesthesia add USD 500 to 1,500 to the total cost compared to endoscopist-administered conscious sedation.
• Hospital Stay Duration: Same-day ERCP is significantly less expensive than inpatient admission. Complications such as pancreatitis or cholangitis extending the stay can double or triple the overall episode cost.
• Insurance Coverage: Therapeutic ERCP is covered by most health insurance plans when performed for a medically documented indication. International patients should obtain pre-authorisation and confirm their insurer covers treatment at overseas facilities before travel.

Use MyMedicPlus to compare ERCP costs across countries, connect with accredited gastroenterologists, and request personalised treatment quotes.

When therapeutic ERCP is not feasible, fails, or is contraindicated, effective alternatives exist depending on the underlying condition:

• Laparoscopic Common Bile Duct Exploration (LCBDE): During laparoscopic cholecystectomy, the surgeon directly accesses and clears the common bile duct under laparoscopic guidance. In experienced centres, stone clearance rates are equivalent to ERCP. LCBDE is preferred when ERCP has failed, anatomy precludes endoscopic access, or concomitant gallbladder removal is planned in the same operative session.
• Percutaneous Transhepatic Cholangiography and Drainage (PTCD): Under ultrasound and fluoroscopic guidance, a needle is passed through the skin and liver into dilated intrahepatic bile ducts. PTCD provides biliary drainage and allows antegrade stent placement or stone removal. It is the primary alternative when ERCP access is impossible due to Roux-en-Y anatomy, duodenal obstruction, or duodenal tumour.
• EUS-Guided Biliary Drainage (EUS-BD): Endoscopic ultrasound is used to create a new transmural drainage pathway — choledochoduodenostomy (bile duct to duodenum) or hepaticogastrostomy (left hepatic duct to stomach). An emerging technique with success rates above 85% in expert centres when ERCP has failed; increasingly adopted as an alternative to percutaneous drainage.
• Open Common Bile Duct Exploration (OCBDE): Reserved for cases where minimally invasive approaches have all failed or are unavailable. Provides definitive biliary access but requires general anaesthesia and carries substantially higher morbidity and longer recovery than endoscopic or laparoscopic alternatives.
• MRCP for Diagnostic Purposes: When the clinical question is whether biliary stones or strictures are present — without a planned therapeutic intervention — MRCP provides equivalent diagnostic accuracy to diagnostic ERCP with no procedural risk. MRCP should be performed before therapeutic ERCP to confirm the indication and plan the intervention.
• Extracorporeal Shock Wave Lithotripsy (ESWL): Used as an adjunct to pancreatic ERCP for large calcified pancreatic duct stones. Fragmentation by ESWL followed by ERCP extraction improves stone clearance rates in chronic pancreatitis from approximately 50% to over 75%.